Education
About Us
Working with TipRanks
Follow Us
Bruker Corporation (BRKR)
:BRKR
BRKR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$30.23 - $72.94
Previous CloseN/A
Volume340.61K
Average Volume (3M)3.50M
Market Cap
$4.86B
Enterprise Value$8.66B
Total Cash (Recent Filing)$92.00M
Total Debt (Recent Filing)$2.44B
Price to Earnings (P/E)61.2
Beta1.23
Next Earnings
Oct 30, 2025EPS Estimate
0.33Last Dividend Ex-Date
Jun 16, 2025Dividend Yield0.62%
Share Statistics
EPS (TTM)0.32
Shares Outstanding151,531,800
10 Day Avg. Volume3,912,938
30 Day Avg. Volume3,502,434
Financial Highlights & Ratios
PEG Ratio-1.04
Price to Book (P/B)4.90
Price to Sales (P/S)2.59
P/FCF Ratio64.22
Enterprise Value/Market Cap1.78
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit5.24
Enterprise Value/Ebitda33.92
Forecast
1Y Price Target
$46.90Price Target Upside46.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Cost SavingsA $100 million+ cost saving program is expected to bolster operating margins in 2026, helping BRKR to deliver significant margin expansion and earnings growth even with flat revenue.
Currency ImpactWeakening of the USD drove FX to a +2.5% tailwind to sales compared to the prior assumption of a +1% tailwind.
Bears Say
Demand PressureBRKR continues to face broad-based demand pressure with no near-term relief in sight across academic, government, industrial, and biopharma sectors.
Funding OutlookWeak end-markets and the outlook for National Institutes of Health funding cloud near-term visibility for BRKR.
Revenue GuidanceBRKR lowered the FY25 guide to $3.43-$3.50bn, factoring a weaker than expected academic/government end market along with worsening biopharma, soft demand in China, and adjustments to tariffs.
Bruker News
BRKR FAQ
What was Bruker Corporation’s price range in the past 12 months?
Bruker Corporation lowest stock price was $30.23 and its highest was $72.94 in the past 12 months.
What is Bruker Corporation’s market cap?
Bruker Corporation’s market cap is $4.86B.
When is Bruker Corporation’s upcoming earnings report date?
Bruker Corporation’s upcoming earnings report date is Oct 30, 2025 which is in 83 days.
How were Bruker Corporation’s earnings last quarter?
Bruker Corporation released its earnings results on Aug 04, 2025. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.412 by -$0.092.
Is Bruker Corporation overvalued?
According to Wall Street analysts Bruker Corporation’s price is currently Undervalued.
Does Bruker Corporation pay dividends?
Bruker Corporation pays a Quarterly dividend of $0.05 which represents an annual dividend yield of 0.62%. See more information on Bruker Corporation dividends here
What is Bruker Corporation’s EPS estimate?
Bruker Corporation’s EPS estimate is 0.33.
How many shares outstanding does Bruker Corporation have?
Bruker Corporation has 151,531,800 shares outstanding.
What happened to Bruker Corporation’s price movement after its last earnings report?
Bruker Corporation reported an EPS of $0.32 in its last earnings report, missing expectations of $0.412. Following the earnings report the stock price went down -8.608%.
Which hedge fund is a major shareholder of Bruker Corporation?
Currently, no hedge funds are holding shares in BRKR
Bruker Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.90 (46.24% Upside)
$46.90 (46.24% Upside)
Blogger Sentiment
Bullish
BRKR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 66.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.11%
12-Months-Change
Fundamentals
Return on Equity
4.43%
Trailing 12-Months
Asset Growth
7.41%
Trailing 12-Months
Company Description
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
BRKR Company Deck
BRKR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call depicted a challenging quarter for Bruker, with significant revenue declines and reduced guidance due to market, tariff, and foreign exchange headwinds. Despite these challenges, Bruker is implementing substantial cost-saving measures and continues to innovate, particularly in diagnostics and new product launches. However, the negative aspects, such as the revenue and EPS decline, along with the challenges in U.S. academic funding, outweigh the positives.View all BRKR earnings summariesBRKR Stock 12 Month Forecast
Average Price Target
$46.90
▲(46.24% Upside)
Technical Analysis
Bio-Rad Laboratories
―
Integer Holdings
―
LivaNova
―
Xtant Medical Holdings
―
Irhythm Technologies
―
Ownership Overview
27.16% Insiders
26.83% Mutual Funds
6.47% Other Institutional Investors
23.31% Public Companies and Individual Investors